Bayer Responds to Studies Linking Birth Control Pills to Blood Clots

Hemera Technologies/Thinkstock(WAYNE, N.J.) -- Following two studies that claim hormones used in newer birth control pills could put women at a greater risk of developing blood clots, Bayer HealthCare Pharmaceuticals, Inc. -- who had three drugs put into question -- has come out with its response.

In a statement released Thursday after the studies were published, the pharmaceutical company said it "re-affirms that the overall body of available scientific evidence continues to provide support that the risk of developing venous thromboembolism, or blood clots, in women using drospirenone-containing combination oral contraceptives is comparable to other combination birth control pills studied."

The studies found that women who take drospirenone-containing pills, like Bayer's Yazmine, Yaz and Ocella, had a two-to-three-fold increased risk of developing clots compared to levonorgestrel-containing pills.

Bayer contended "that the manner in which the authors applied the study methodology reported in these two publications and the databases used provide less reliable conclusions than are available from existing scientific evidence."

The company also said the findings "do not change the overall assessment about the safety of Bayer's oral contraceptives."

Copyright 2011 ABC News Radio

Bayer Tests Fat-Loss Injection for Double Chin

Photo Courtesy - Getty Images(LEVERKUSEN, Germany) -- A simple injection in the neck to get rid of that double chin? Sounds too good to be true, and that very well may be the case concerning Bayer's newest fat-dissolving injectable, ATX-101, which is beginning phase III trials in Europe.

The upcoming multi-center, randomized, double-blind, placebo-controlled study will test the efficacy of ATX-101 for eliminating localized fat under the chin, known as submental fat. The companies announced Monday that they are enrolling patients for the trial in France, Germany, Belgium, Spain, Italy and the U.K.

The drug utilizes half of the two-drug, off-label cocktail used for the notoriously problematic fat-dissolving injectable Lipodissolve that prompted a public warning by the Food and Drug Administration in spring 2010.

Lipodissolve, which was marketed as a quick and easy "lunchtime lipo" procedure a few years back, utilized two chemicals, phosphatidylcholine (PC) and deoxycholate (DC), neither of which were FDA approved for fat elimination.

ATX-101, is just sodium deoxycholate (DC in solution).

Research has shown PC actually inhibits the fat-dissolving effects of DC, so researchers are testing the efficacy of DC alone for fat elimination, said KYTHERA Biopharmaceuticals, Inc., which teamed with Bayer in August 2010 for the upcoming trial.

KYTHERA hopes ultimately to bring an FDA-approved compound for injectable fat elimination to the U.S. market. Two phase II trials in humans have been done in the U.S. so far and a third is underway.

"We are very pleased with the progress that has been made in Europe with ATX-101," Keith Leonard, KYTHERA's president and CEO, said in a press release on the trial. "The initiation of these Phase III studies marks an important milestone in our collaboration with Intendis and further demonstrates the potential of ATX-101 as a first-in-class injectable drug for localized fat reduction."

But plastic surgeons are wary of this renewed attempt to test DC as a cosmetic fat-dissolver.

"I would be very cautious. Even if it's approved in Europe, people will start purchasing it and sneaking into the U.S. illegally," said Dr. Darrick Antell, a plastic surgeon at Roosevelt Hospital in New York and a spokesman for the American Society of Plastic Surgeons. "There's no doubt in my mind that if it's approved for the small area [under the chin], then people will start using for large areas and I have no doubt that there will invariably be adverse effects. [Injectable fat-dissolvers] need a lot more work. People who would use this sort of medicine at this point would be like driving ahead of your headlights."

Copyright 2011 ABC News Radio